CN114127077A - 用作Cdc7抑制剂的四并环类化合物 - Google Patents

用作Cdc7抑制剂的四并环类化合物 Download PDF

Info

Publication number
CN114127077A
CN114127077A CN202080052521.5A CN202080052521A CN114127077A CN 114127077 A CN114127077 A CN 114127077A CN 202080052521 A CN202080052521 A CN 202080052521A CN 114127077 A CN114127077 A CN 114127077A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
isomer
acceptable salt
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080052521.5A
Other languages
English (en)
Other versions
CN114127077B (zh
Inventor
卢伦
李刚
胡利红
丁照中
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN114127077A publication Critical patent/CN114127077A/zh
Application granted granted Critical
Publication of CN114127077B publication Critical patent/CN114127077B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

一类作为Cdc7抑制剂的四并环类化合物，具体公开了式(I)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202080052521.5A 2019-08-20 2020-08-20 用作Cdc7抑制剂的四并环类化合物 Active CN114127077B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910769786 2019-08-20
CN2019107697866 2019-08-20
PCT/CN2020/110305 WO2021032170A1 (zh) 2019-08-20 2020-08-20 用作Cdc7抑制剂的四并环类化合物

Publications (2)

Publication Number Publication Date
CN114127077A true CN114127077A (zh) 2022-03-01
CN114127077B CN114127077B (zh) 2023-08-01

Family

ID=74659972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052521.5A Active CN114127077B (zh) 2019-08-20 2020-08-20 用作Cdc7抑制剂的四并环类化合物

Country Status (5)

Country Link
US (1) US20220389026A1 (zh)
EP (1) EP4006036A4 (zh)
JP (1) JP2022546294A (zh)
CN (1) CN114127077B (zh)
WO (1) WO2021032170A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070112020A1 (en) * 2005-11-11 2007-05-17 Pharmacia Italia S.P.A. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20080161559A1 (en) * 2006-12-29 2008-07-03 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2011102399A1 (ja) * 2010-02-17 2011-08-25 武田薬品工業株式会社 複素環化合物
CN110088100A (zh) * 2016-11-08 2019-08-02 癌症研究科技有限公司 作为cdc7抑制剂的嘧啶酮衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531757A (ja) * 2004-03-30 2007-11-08 カイロン コーポレイション 抗癌剤としての置換チオフェン誘導体
US20070142414A1 (en) * 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US20090030196A1 (en) * 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
US20220235068A1 (en) * 2019-05-30 2022-07-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compounds as cdc7 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070112020A1 (en) * 2005-11-11 2007-05-17 Pharmacia Italia S.P.A. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20080161559A1 (en) * 2006-12-29 2008-07-03 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2011102399A1 (ja) * 2010-02-17 2011-08-25 武田薬品工業株式会社 複素環化合物
CN102844320A (zh) * 2010-02-17 2012-12-26 武田药品工业株式会社 杂环化合物
CN110088100A (zh) * 2016-11-08 2019-08-02 癌症研究科技有限公司 作为cdc7抑制剂的嘧啶酮衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李志广 等: "抗人CDC7 单克隆抗体的制备与鉴定", 《中国当代医药》 *

Also Published As

Publication number Publication date
WO2021032170A1 (zh) 2021-02-25
CN114127077B (zh) 2023-08-01
EP4006036A1 (en) 2022-06-01
JP2022546294A (ja) 2022-11-04
EP4006036A4 (en) 2022-09-14
US20220389026A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
JP7394074B2 (ja) 治療用化合物
JP7377798B2 (ja) ｃ－ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物
EP3374350B1 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
EP3470409B1 (en) Benzotriazole-derived alpha and beta-unsaturated amide compound used as tgf-beta ri inhibitor
TWI749126B (zh) Cdk4/6抑制劑
EP4092024A1 (en) Pyrimidine-4(3h)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology
CA3137985A1 (en) Substituted pyrrolo [2, 3-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
EP3971190A1 (en) Heterocycle-fused pyrimidine derivative and use thereof
US20230102081A1 (en) Compound as cyclin-dependent kinase 9 inhibitor and use thereof
CN115942937A (zh) 嘧啶并环类化合物
CN113874379B (zh) 作为Cdc7抑制剂的四并环类化合物
EP4046999A1 (en) Aminopyrimidine compound as cdk2/4/6 triple inhibitor
JP7340519B2 (ja) ｍＴＯＲＣ１／２二重阻害剤としてのピリドピリミジン系化合物
CN114008046A (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
WO2020078455A1 (zh) Tlr8激动剂
AU2017280412B2 (en) Substituted pyrrolo (2, 3-D) pyridazin-4-ones and pyrazolo (3, 4-D) pyridazin-4-ones as protein kinase inhibitors
CN114127077A (zh) 用作Cdc7抑制剂的四并环类化合物
US10654868B2 (en) Dihydropyrazole azepine compound serving as Akt inhibitor
US20140038991A1 (en) Protein Kinase Inhibitors
TW202136267A (zh) Ｂｒｕｔｏｎ酪胺酸激酶（ＢＴＫ）抑制劑
CN111393447B (zh) 一种嘧啶并吡唑类化合物、其制备方法及应用
CN107614501A (zh) 羟基嘌呤类化合物及其应用
US20220354859A1 (en) Substituted imidazoquinoxaline compounds and uses thereof
CN115215861A (zh) 一种芳杂环取代的炔烃类化合物及其制备方法和用途
FR2888579A1 (fr) Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant